Patrick Toomey said...

It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.

Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.

07/19/2011

More Patrick Toomey Quotes

We also need to work to ensure regulatory clarity for digital assets.

We should not pay for an infrastructure package by borrowing billions more dollars, but that is precisely what happened ...

But that does not mean that Congress should be throwing even more billions of Federal taxpayer dollars at them to build ...

our heart breaks for you and your family like it does for the several million Ukrainians that have been forced from thei...